FindTrial
Sign In

Ipilimumab and nivolumab

DRUG5 trials

Sponsors

Italian Network for Tumor Biotherapy Foundation, The Netherlands Cancer Institute, Leiden University Medical Center, PrECOG, LLC., University of Hawaii

Conditions

Brain MetastasesCancerHepatocellular Carcinoma (HCC)Malignant Pleural MesotheliomaMesotheliomaNeoplasiaNeoplasmPleural Mesothelioma

Phase 1

PHP and Immunotherapy in Metastasized UM
Active, not recruitingNCT04283890
Leiden University Medical CenterUveal Melanoma, Metastatic
Start: 2019-12-04End: 2029-12-31Target: 83Updated: 2025-09-09
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
Not yet recruitingNCT07075120
University of HawaiiHepatocellular Carcinoma (HCC)
Start: 2026-04-01End: 2027-12-31Target: 15Updated: 2026-03-31

Phase 2

The Drug Rediscovery Protocol (DRUP Trial)
RecruitingNCT02925234
The Netherlands Cancer InstituteCancer, Neoplasia, Neoplasm +1
Start: 2016-08-31End: 2027-12-31Target: 1550Updated: 2024-01-24

Phase 3

A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
NCT02460068
Italian Network for Tumor Biotherapy FoundationBrain Metastases
Start: 2012-12-31End: 2020-01-31Target: 168Updated: 2015-06-02
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
CompletedNCT04334759
PrECOG, LLC.Malignant Pleural Mesothelioma, Mesothelioma, Pleural Mesothelioma
Start: 2021-02-18End: 2025-06-30Updated: 2026-01-22

Related Papers

The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).
2025-01-073 citations
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Clinical Cancer Research2024-07-184 citations
Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Clinical Cancer Research2024-06-272 citations
Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.
Journal of Clinical Oncology2024-06-013 citations
The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).
Journal of Clinical Oncology2024-06-01
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Clinical Cancer Research2024-04-173 citations
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma
JAMA Oncology2024-02-1539 citations
Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Journal of Clinical Oncology2023-06-013 citations
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
Journal of Clinical Oncology2023-06-01
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
2023-03-0410 citations
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
BMC Cancer2023-02-2223 citations
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.
2023-01-0922 citations
Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study
BMC Medical Genomics2022-11-046 citations
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
Journal of Clinical Oncology2022-06-011 citations
Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): First results of the phase Ib part of the CHOPIN trial.
Journal of Clinical Oncology2022-06-011 citations
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
2022-05-226 citations
First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.
Journal of Clinical Oncology2022-02-162 citations
Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
2022-02-1316 citations
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
2022-01-2536 citations
Promising Therapeutic Strategy in Malignant Pleural Mesothelioma
Oncology Times2022-01-18

8 more papers not shown